Marisa McGrath

TL;DR: At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum, and the addition of adjuvant resulted in enhanced immune responses, was antigen dose–sparing, and induced a T helper 1 (Th1) response.

TL;DR: The authors identified shared biology and host-directed drug targets to prioritize therapeutics with potential for rapid deployment against current and future coronavirus outbreaks, and found that individuals with genotypes corresponding to higher soluble IL17RA levels in plasma are at decreased risk of COVID-19 hospitalization.

TL;DR: In this paper, the authors determined the structures of two human monoclonal antibodies-AZD8895 and AZD1061-which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor-binding domain (RBD) of SARS-CoV-2 to define the genetic and structural basis of neutralization.

TL;DR: In this paper, a microfluidic bronchial-airway-on-a-chip line was used to model the human airway epithelium and pulmonary endothelium to model viral infection, strain-dependent virulence, cytokine production and the recruitment of circulating immune cells.

TL;DR: In this paper, a phosphate prodrug PF-07304814 was developed to inhibit coronavirus family 3CL protease activity with selectivity over human host protease targets.